IBL Tool - Digital Library

Digital Library

Journal description

All volumes of the corresponding journal

All issues of the corresponding volume

All articles of the corresponding issues

205 results found

no	title	author	magazine	year	volume	issue	page(s)	type
1	35 Abnormal chromatin clumping in leucocytes syndrome with a high fraction of bone marrow cells in S-phase and In vitro autonomous growth	Valleio, C		1997	21	1S1	p. S9	article
2	107 Abnormal motility patterns of neutrophils in myelodysplastic syndromes identified by image analysis	Azzarà, A		1997	21	1S1	p. S28	article
3	132 A case of a t(1;3)(p36:q21) in chronic myelomonocytic leukemia with thrombocytosis and TPO gene expression in malignant cells	Ciolli, S.		1997	21	1S1	p. S34	article
4	169 Aggressive chemotherapy in MDS: The Düsseldorf experience	Aul, C.		1997	21	1S1	p. S45	article
5	196 Allogeneic bone marrow transplantation for adults with primary myelodysplastic syndrome: Evaluation of prognostic factors	Shepherd, JD		1997	21	1S1	p. S52	article
6	163 Amifostine in low-risk and combined therapy with gemcitabine in high-risk myelodysplastic syndromes	Sezer, O.		1997	21	1S1	p. S42	article
7	36 AML post RAEB with intense granulation alterations	Rozman, M.		1997	21	1S1	p. S10	article
8	51 Analysis of prognostic factors for low risk myelodysplastic syndrome; a proposal of new scoring system	Tomonaga, M.		1997	21	1S1	p. S14	article
9	170 Anti-AML chemotherapy in high-risk MDS: The M.D. Anderson cancer center experience	Estey, E.		1997	21	1S1	p. S45	article
10	79 Antigenic characterization of bone marrow endosteal cells: A stem cell hypothesis reevaluated	Walchshofer, S.		1997	21	1S1	p. S21	article
11	151 A patient-oriented approach to the use of erythropoietin in myelodysplastic syndromes	Cazzola, Mario		1997	21	1S1	p. S39	article
12	101 Apoptosis and fas antigen (CD95) expression in myclodysplasia	Bouscary, D.		1997	21	1S1	p. S26	article
13	21 Association between myelodysplastic syndromes and inflammatory bowel diseases: report of 4 new cases and review of previously reported cases	Wattel, E		1997	21	1S1	p. S6	article
14	40 Atypical sweet's syndrome (SS) in a patient with AML secondary to a RAEB-T	Pagano, L.		1997	21	1S1	p. S11	article
15	34 Atypical variants of MDS in children	Torubarova, N.		1997	21	1S1	p. S9	article
16	Author index			1997	21	1S1	p. I-VIII	article
17	195 Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS)	Wartel, E.		1997	21	1S1	p. S52	article
18	9 Benzene exposure and risk of MDS/AML	Smith, M.T.		1997	21	1S1	p. S3	article
19	77 Biological consequences of stromal abnormalities in the myelodysplastic syndrome (MDS): Its influence on the hematopoietic dysregulation	Silverman, L.R.		1997	21	1S1	p. S20	article
20	193 BMT in MDS: The experience of the EBMT	Boogaerts, Marc A.		1997	21	1S1	p. S51	article
21	90 Bone marrow culture studies in myelodysplastic syndromes	de Souza Femandez, Teresa		1997	21	1S1	p. S24	article
22	192 Bone marrow transplantation for myelodysplasia: The IBMTR data	Sierra, J.		1997	21	1S1	p. S51	article
23	200 Bone marrow transplantation in patients with myelodysplastic syndrome. A single center experience	Cermak, J.		1997	21	1S1	p. S53	article
24	127 Both inhaled and ingested substances are involved in secondary myelodysplastic syndromes (MDS) with 6p changes	Ciolli, S.		1997	21	1S1	p. S33	article
25	202 Calcitriol in the treatment of myelodysplastic syndromes	Mellibovsky, L.		1997	21	1S1	p. S55	article
26	177 Carboplatin(CBDCA) alone or in combination in the treatment of acute myeloid leukema (AML) secondary to myelodysplastic syndromes and in other high risk AML	Larrea, L.		1997	21	1S1	p. S47	article
27	102 CD34+ cells in myelodisplastic syndromes with lower percent of blasts are characterized by high spontaneus rate of apoptosis	Ricciardi, M.R.		1997	21	1S1	p. S27	article
28	61 CFU-GM growth and survival in 258 patients with myelodysplastic syndromes	Jelínek, J.		1997	21	1S1	p. S16	article
29	172 Chemotherapy of adult chronic myelomonocytic leukemia (CMML)	Wattel, E.		1997	21	1S1	p. S46	article
30	188 Chemotherapy-related infections in myelodysplastic syndromes (MDS) and acute myeloid leukemia secondary to MDS (sAML). A study of 27 patients	Jarque, I.		1997	21	1S1	p. S50	article
31	119 Childhood myelodysplasia: Cytogenetic and fish studies	Mancini, M.		1997	21	1S1	p. S31	article
32	58 Chromosomal abnormalities in patients with myelodysplastic syndromes of low and high cytologic risk	Rus, G. Pérez		1997	21	1S1	p. S16	article
33	112 Chromosomal abnormalities in secondary MDS/AML relationships to prior drugs and radiation	Pedersen-Bjergaard, Jens		1997	21	1S1	p. S29	article
34	122 Chromosome 5Q31-specific DNA probe to detect intertitial long arm deletions of chromosome	Bernasconi, P.		1997	21	1S1	p. S32	article
35	30 Chronic myelomonocytic leukemia as a secondary myelodysplasia in a chronic lymphoid leukemia case	Brunel, V		1997	21	1S1	p. S8	article
36	28 Chronic myelomonocytic leukemia: Clinical and hematopathological features of 27 patients	Marisavljevic, D.		1997	21	1S1	p. S8	article
37	181 Cladribine (2-CDA) is active in “high-risk”-chronic myelomonocytic leukemia and secondary or relapsed acute myelo(Mono)cytic leukemia	Krieger, O.		1997	21	1S1	p. S48	article
38	31 Classification of chronic neutrophilic leukemia: — A report of 2 patients and review of 73 cases from the literature	Ben-Tal, O.		1997	21	1S1	p. S8	article
39	24 Clinical and biological profile of 55 patients with Refractory Anemia with Ring Sideroblasts	Richart, A.		1997	21	1S1	p. S7	article
40	137 Clinical potential of mutant ras	Mufti, Ghulam J.		1997	21	1S1	p. S35	article
41	152 Clinical results of the use of different cytokines in MDS	Hellström-Lindberg, Eva		1997	21	1S1	p. S39	article
42	120 Clonal evolution in myelodysplasic syndromes	Rus, G. Pérez		1997	21	1S1	p. S31	article
43	71 Clonality of hematopoiesis in myelodysplasia	Willemze, R.		1997	21	1S1	p. S19	article
44	125 Clonal karyotypic abnormalities after autologous transplantation (AT)	Amigo, M.L.		1997	21	1S1	p. S32	article
45	2 Codification of dysmyelopoiesis in myelodysplastic syndromes	Flandrin, Georges		1997	21	1S1	p. S1	article
46	7 Combined morphological, immunological and cytogenetic techniques in the diagnosis of myelodysplastic syndromes (MDS)	Woessner, S.		1997	21	1S1	p. S2	article
47	50 Correlation of karyotype with clinical features and prognosis in 349 patients with MDS	Haase, D.		1997	21	1S1	p. S14	article
48	33 Criteria for the differential diagnosis between aplastic anemia and hypocellular myelodysplasia	Lorand-Metze, I.		1997	21	1S1	p. S9	article
49	114 Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure	Stafford, DA		1997	21	1S1	p. S30	article
50	117 Cytogenetic and molecular study in primary myelodysplastic syndrome	de Souza Fernandez, Teresa		1997	21	1S1	p. S30	article
51	4 Cytogenetic methods (conventional and FISH) for the study of Myelodysplastic Syndromes	Jhanwar, Suresh C.		1997	21	1S1	p. S1	article
52	201 Cytogenetics to monitor disease outcome after allo-BMT in patients with myelodysplastic syndrome (MDS)	Bernasconi, P.		1997	21	1S1	p. S53	article
53	116 Cytogenetic studies in 429 myelodysplastic syndromes:Prognostic value	Solé, F.		1997	21	1S1	p. S30	article
54	126 Cytogenetic studies in secondary leukemia: Report of 28 cases from one center and comparison with the results in de novo acute myeloid leukemia (AML)	Granada, I		1997	21	1S1	p. S33	article
55	118 Cytogenetic study and prognostic impact of complex karyotypes in 22 myelodysplastic syndromes	Prieto, E.		1997	21	1S1	p. S31	article
56	124 Cytogenetic study of 36 patients with secondary myelodysplastic syndrome (MDS)/acute myeloid leukemia(AML)	Lun˜o, E.		1997	21	1S1	p. S32	article
57	96 Cytokine production in vivo in mds and AML patients	Preisler, H.D.		1997	21	1S1	p. S25	article
58	26 Cytoplasmic abnormalities of erythroblasts in a patient with refractory anaemia with ring sideroblasts	Florensa, L.		1997	21	1S1	p. S7	article
59	108 Defective actin polymerization in neutrophils from patients with myelodysplastic syndromes	Carulli, G.		1997	21	1S1	p. S28	article
60	109 Deficit in integrin expression on PMNs in patients with myelodyslastic syndromes	Ricevuti, G.		1997	21	1S1	p. S28	article
61	140 Deletion of the pura gene, encoding the single-stranded DNA-binding protein purα, in myelodysplastic syndrome (MDS) and myeloid leukemias	Lezon-Geyda, K.A.		1997	21	1S1	p. S36	article
62	129 Deletion sq- in a patient with a secondary myelodysplastic syndromes post multiple myeloma	Solé, Franceac		1997	21	1S1	p. S33	article
63	144 Detection of telomerase activity in cell in myelodysplastic syndromes: Application of in situ telomeric repeat amplification protocol (TRAP)	Ohyashiki, K.		1997	21	1S1	p. S37	article
64	68 Diagnostic and prognostic significance of elevated percent of fetal hemoglobin containing erythrocytes in patients with myelodysplastic syndromes	Śledziowski, P.		1997	21	1S1	p. S18	article
65	78 Disturbed interaction between hematopoiesis and bone marrow microenvironment in myelodysplastic syndromes (MDS)	Kunert, Ch.		1997	21	1S1	p. S21	article
66	105 DNA image cytometry in MDS bone marrow smears	Widell, S.		1997	21	1S1	p. S27	article
67	27 Does WBC count really define two different subtypes of chronic myelomonocytic leukemia (CMML)? Analysis of a series of 119 patients	Cervera, J.		1997	21	1S1	p. S7	article
68	131 Duplication of DER(8)t(8:12)(q12:p13) and loss of ETV6 gene in a patient with refractory anaemia	Hernández, J.M.		1997	21	1S1	p. S34	article
69	187 Effective combined chemotherapy in children with juvenile chronic myelomonocytic leukaemia	de Heredia, C. Diaz		1997	21	1S1	p. S49	article
70	86 Effects of rHumegakaryocyte growth and development factor (rHuMGDF) on in vitro proliferation of megakaryocyte progenitors in myelodysplastic syndromes (MDS)	Fontenay-Roupie, M.		1997	21	1S1	p. S23	article
71	87 Effects of three new recombinant. Human GM-CSF/Erythropoietin (EPO) hybrid molecules on in vitro growth of hemopoietic progenitors in myelodysplastic syndromes (MDS)	Scalzulli, P.R.		1997	21	1S1	p. S23	article
72	74 Enigmatic role(s) of programmed cell death (apoptosis) in myelodysplasias	Yoshida, Yataro		1997	21	1S1	p. S20	article
73	16 Epidemiology of myelodysplastic syndromes in a French general hospital	Bauduer, F.		1997	21	1S1	p. S5	article
74	83 Erythropoiesis, erythrokinetics and erytrocytokinetics in myelodysplastic syndromes	Lipsic, T.		1997	21	1S1	p. S22	article
75	110 Established chromosome changes in myelodysplastic syndromes	Van den Berghe, H.		1997	21	1S1	p. S29	article
76	97 Expression of CD36 (GPIIIb) on platelets in MDS	Neuwirtová, R.		1997	21	1S1	p. S25	article
77	104 Expression of CD34, P170, and apoptosis-controlling proteins (BCL-2, BAX, BCL-X, BAD, ICE and CPP32) in myelodysplastic syndromes	Campos, L.		1997	21	1S1	p. S27	article
78	100 Expression of FAS/APO-1/CD95 antigen and its function in myelodysplastic syndromes	Lepelley, P.		1997	21	1S1	p. S26	article
79	99 Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS)	Lepelley, P.		1997	21	1S1	p. S26	article
80	98 Expression of the myeloid antigens on bone marrow cells in patients with myelodisplastic syndromes	Masljak, Z.		1997	21	1S1	p. S26	article
81	103 Extensive apoptosis of CD34+ marrow cells in patients with mds is related to low colony forming cell number and probably to hematopoietic deficiency	Kourakli-Symeonidis, A.		1997	21	1S1	p. S27	article
82	22 Familial myelodysplastic syndromes: A key to understanding leukaemogenesis?	Mijovic, A.		1997	21	1S1	p. S6	article
83	91 Ferrokinetic studies in myelodysplasia suggests a dissociation of proliferation and differentiation in erythropoiesis	Brada, S.		1997	21	1S1	p. S24	article
84	182 Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of refractory anemia with excess of blasts in transformation (RAEB-t)	Ferrara, F.		1997	21	1S1	p. S48	article
85	161 G-CSF treatment after intensive chemotherapy in high risk myelodysplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS: A randomized study	Bernasconi, C.		1997	21	1S1	p. S42	article
86	11 Glutathione S transferase theta 1 (GSTT1) gene defects in myelodysplastic syndromes (MDS) and their correlation with Kryotype and exposure to potential carcinogens	Preudhomme, C.		1997	21	1S1	p. S3	article
87	60 Hematologic, histologic, cytogenetic, and survival analysis of 60 patients with primary myelodysplastic syndromes (MDS)	Souza, J.M.		1997	21	1S1	p. S16	article
88	81 Hemopoietic microenvironment in refractory anemia with increased number of blasts (RAEB)	Rugal, V.		1997	21	1S1	p. S21	article
89	199 Hemopoietic progenitor cells transplantation from HLA-identical siblings for myelodysplasia: Outcome of 11 patients from a single institution	Martínez, C.		1997	21	1S1	p. S53	article
90	23 Heterogeneity of acquired idiopathic sideroblastic anemia (AISA): Results of a prospective follow-up study in 189 patients	Aul, C.		1997	21	1S1	p. S6	article
91	139 Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome C oxidase in two patients with acquired idiopathic sideroblastic anaemia	Gattermann, N.		1997	21	1S1	p. S36	article
92	37 High peripheral but low marrow blasts: Myelodysplastic syndrome or peripheral acute leukemia?	Ündar, B.		1997	21	1S1	p. S10	article
93	171 Idarubicin, fludarabine, cytarabine and G-CSF (FLAG-IDA) for the treatment of high risk MDS or AML	Parker, J.E.		1997	21	1S1	p. S45	article
94	85 Identification of a group of thrombocytopenic MDS patients. Candidate for in vivo treatment with PEG-rHuMGDF	Fontenay-Roupie, M.		1997	21	1S1	p. S22	article
95	73 Immumophenotyping in MDS	del Can˜izo, M.C.		1997	21	1S1	p. S19	article
96	70 Immunology of MDS, towards a DNA vaccine	Hamblin, TJ		1997	21	1S1	p. S19	article
97	165 Immunotherapy with low-dose interleukin-2 in patients with myelodysplastic syndromes RAEB and RAEB-T (an ongoing pilot study)	Faber, E.		1997	21	1S1	p. S43	article
98	59 Impact of advanced age on the prognostic value of karyotype and scoring systems in primary myelodysplastic syndromes (p-MDS)	Parlier, V.		1997	21	1S1	p. S16	article
99	48 Impact of histopathology on diagnosis, clinics and outcome of myelodysplastic syndromes	Georgii, A.		1997	21	1S1	p. S13	article
100	20 Incidence of cancer and body iron stores in sideroblastc anemia	Sˇisˇková, M.		1997	21	1S1	p. S6	article
101	10 Increasing incidence of MDS: Real or fictitious?	Aul, C.		1997	21	1S1	p. S3	article
102	176 Induction of complete hematological and cytogenic remissions in myelopysplastic syndromes and CMML by topotecan	Baran, M		1997	21	1S1	p. S47	article
103	189 Infectious complications after intensive remission induction in advanced myelodysplastic syndromes and de novo acute myeloid leukemia	Böhme, A.		1997	21	1S1	p. S50	article
104	186 Intensive antileukemic treatment and/or allogeneic or autologous bone marrow or PBSC transplantation in myelodysplastic syndromes and in post-MDS acute myeloid leukaemia	Finelli, C.		1997	21	1S1	p. S49	article
105	174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML	Ganser, A.		1997	21	1S1	p. S46	article
106	184 Intensive chemotherapy in de novo MDS. Outcome of patients who achieved partial remission (PR)	Wattel, E.		1997	21	1S1	p. S49	article
107	173 Intensive chemotherapy with quinine in myelodysplastic syndromes (MDS)	Fenaux, P.		1997	21	1S1	p. S46	article
108	153 Interleukin 3 (IL-3) and newer hematopoietic growth factors in the management of myelodysplastic syndrome (MDS)	Saba, Hussain I.		1997	21	1S1	p. S40	article
109	84 In vitro effect of c-mpl-ligand on CD34 positive cells isolated from patients with chronic myelodysplastic syndromes (MDS)	Hofmann, W.-K.		1997	21	1S1	p. S22	article
110	133 Karyotype studies in patients with myelodysplastic syndromes	Salamantchouk, Z.		1997	21	1S1	p. S34	article
111	1 Laboratory presentation and morphological characteristics of myelodysplastic syndromes	Vallespí, Teresa		1997	21	1S1	p. S1	article
112	156 Lenograstim associated or not to ARA-C (3mg/m2X2) as therapy for poor prognosis refractory anemia with excess of blasts (RAEB)	Chomienne, C.		1997	21	1S1	p. S40	article
113	63 Leukemic risk im patients aged less than 60 years with myelodysplastic syndromes (MDS): A multivariate analysis of prognostic factors in 140 patients	Sanz, G.F.		1997	21	1S1	p. S17	article
114	43 Leukemoid reaction mimicking acute promyelocytic leukemia in a patient with myelodysplastic syndrom	Carral, A.		1997	21	1S1	p. S11	article
115	185 Long term survival after intensive chemotherapy in de novo MDS: Lille's experience	Debotton, S.		1997	21	1S1	p. S49	article
116	158 Long term treatment of intermediate risk myelodys-plastic syndrome with rhG-CSF and rhEPO: Interim report of an ongoing randomized phase III trial	Lentini, G.		1997	21	1S1	p. S41	article
117	160 Low-dose Ara-C and G,M-CSF in high-risk myelodysplastic syndromes and acute leukaemia of the old	Sastre, JL		1997	21	1S1	p. S41	article
118	175 Low dose 5-AZA-′2-deoxycytidine in eldery patients with high risk MDS	Wijermans, P.		1997	21	1S1	p. S46	article
119	168 Low-dose chemotherapy in MDS	Hellström-Lindberg, Eva		1997	21	1S1	p. S45	article
120	88 Low stem cell factor plasma levels are correlated with in vitro leukemic growth in myelodysplastic syndromes	Cortelezzi, A.		1997	21	1S1	p. S23	article
121	106 Mast cell (MC) lineage involvement in myelo-dysplastic syndromes: Diagnostic utility of tryptase staining	Valent, P.		1997	21	1S1	p. S28	article
122	82 Megakaryopoiesis in myelodysplastic syndromes: Morphological and immunocytochemical features	Lorand-Metze, I.		1997	21	1S1	p. S22	article
123	203 Molecular biology of elderly AML and its relationship to myelodysplasia (MDS)	Willman, Cheryl L.		1997	21	1S1	p. S55	article
124	136 Molecular biology of elderly AML and its relationship to myelodysplasia (MDS)	Willman, Charyl L		1997	21	1S1	p. S35	article
125	141 Molecular definition of two narrow interval at 7q22.1 and 7Q34 associated with myelodysplasia	Cotter, F.E.		1997	21	1S1	p. S36	article
126	135 Molecular genetics of myeloid disorders characterized by −7/del(7q)	Shannon, K.		1997	21	1S1	p. S35	article
127	134 Molecular mapping of the DEL(5Q) in myelodysplastic syndromes	Le Beau, M.M.		1997	21	1S1	p. S35	article
128	113 Morphological, cytogenetic, molecular and etiological features of the ≪ 17p syndrome ≫ in MDS	Preudhomme, C.		1997	21	1S1	p. S29	article
129	18 Morphological features of myelodysplasia after autologous transplantation	Amigo, M.L.		1997	21	1S1	p. S5	article
130	62 Multivariate analysis of prognostic factors for survival in 140 patients aged less than 60 years with myelodysplastic syndromes (MDS)	Sanz, G.F.		1997	21	1S1	p. S17	article
131	138 Mutant RAS or FMS confer abnormal growth in haematopoietic cells: Poor clinical outcome in myelodysplasia with RAS, FMS and p53 mutations	Padua, R.A.		1997	21	1S1	p. S36	article
132	145 Mutations of the MSH2 gene in myelodysplastic syndrome (MDS)	Duthoit, E.		1997	21	1S1	p. S37	article
133	57 Myelodisplastic syndromes prognostic factors in 133 patients with cytogenetic study	Rus, G. Pérez		1997	21	1S1	p. S15	article
134	19 Myelodysplastic syndrome after autologous stem cell transplantation	Laurenti, L.		1997	21	1S1	p. S5	article
135	147 Myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria; phenotypic and molecular search for an association	Iwanaga, M.		1997	21	1S1	p. S38	article
136	121 Myelodysplastic syndrome and 17P deletion	Stamatoullas, A.		1997	21	1S1	p. S31	article
137	39 Myelodysplastic syndrome and thrombotic thrombocytopenic purpura	Ündar, L.		1997	21	1S1	p. S10	article
138	45 Myelodysplastic syndrome in its fibrotic variant: A borderline to chronic myeloproliferation	Wilezak, W.		1997	21	1S1	p. S12	article
139	148 Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) supervening previously untreated chronic B-lymphocytic leukemia (B-cll): Demonstration of the concomitant presence of two different malignant clones by immunologic and molecular analysis	Schwarzmeier, J.D.		1997	21	1S1	p. S38	article
140	194 Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: Outcome of 90 adult patients	Alessandrino, E.P.		1997	21	1S1	p. S52	article
141	17 Myelodysplastic syndromes in Thailand: A retrospective pathologic and clinical analysis of 117 cases	Intragumtornchai, Tanin		1997	21	1S1	p. S5	article
142	64 Myelodysplastic syndromes (MDS) in patients aged>20 and <40 years	Latagliata, R.		1997	21	1S1	p. S17	article
143	44 Myelodysplastic syndromes with bundles of Auer rods. Study of two cases	Domingo-Claros, A		1997	21	1S1	p. S12	article
144	123 Neutrophil dysplasia is not a feature of the abnormal chromosomal clones in myelodysplastic syndromes	Hast, R.		1997	21	1S1	p. S32	article
145	115 New biological insights into chromosome 21 rearrangements in the myelodysplastic syndrome (MDS)	Naifeld, V.		1997	21	1S1	p. S30	article
146	38 Nodular lesions of monocytic component in myelodysplastic syndrome (MDS)	Mongkonsritragoon, W.		1997	21	1S1	p. S10	article
147	157 Non-clonal response to erythropoietin in myelodysplastic syndromes	Eriksson, M.		1997	21	1S1	p. S41	article
148	12 Occupational and environmental exposures and the myelodysplastic syndromes: A case-control study	West, RR		1997	21	1S1	p. S4	article
149	15 Occupational and environmental risk factors of MDS = a case control study	Nisse, C.		1997	21	1S1	p. S4	article
150	178 Oral idarubicin administration as monochemotherapy in myelodisplastic syndromes	Petrini, M.		1997	21	1S1	p. S47	article
151	198 Outcome of bone marrow transplantation in myelodysplastic syndrome or secondary acute myeloid leukemia	Lorand-Metze, I		1997	21	1S1	p. S53	article
152	146 Oxidative DNA damage and low reduced glutathione concentration is associated with elevated tumor necrosis factor alpha concentration in myelodysplasia	Bowen, D.		1997	21	1S1	p. S38	article
153	143 Patterns of expression of RAS, P53 and MDM2 proteins in myelodysplastic syndromes	Silva, E.S.		1997	21	1S1	p. S37	article
154	13 Pediatric myelodysplasia: Characteristics and prognostic factors	Ortega, Juao J.		1997	21	1S1	p. S4	article
155	80 Phenotypic analysis of endosteal cells in myelodysplastic syndromes and other hemopoietic disorders	Sillaber, C.		1997	21	1S1	p. S21	article
156	94 Plasma thrombopoietin (TPO) level in patients with myelodysplastic syndromes (MDS)	Ogata, K.		1997	21	1S1	p. S25	article
157	130 Polysomy for a 20q- chromosome masked by multiple markers in a case of secondary MDS	Falzetti, D.		1997	21	1S1	p. S34	article
158	162 Potential for use of amifostine in the treatment of poor prognosis acute myelogenous leukemia	Preisler, H.D.		1997	21	1S1	p. S42	article
159	5 Primary chromosomal abnormalities in myelodysplastic syndromes (MDS)	Mecucci, Cristina		1997	21	1S1	p. S2	article
160	54 Primary myelodysplastic syndromes : A retrospective study of treatment response and prognostic features in 39 patients in the western region of Algeria	Bekadja, M.A		1997	21	1S1	p. S15	article
161	52 Primary myelodysplastic syndromes: Multivariate analysis of prognostic factors in Brazilian patients	Velloso, E.R.P.		1997	21	1S1	p. S14	article
162	14 Problems in the classification of CMML. Dysplastic vs profliferative type	Germing, U.		1997	21	1S1	p. S4	article
163	55 Prognosis in myelodysplastic syndromes with specific reference to karyotypes — Experience on 296 patients from a single institution	Pfeilstöcker, M.		1997	21	1S1	p. S15	article
164	47 Prognostic factors in younger patients with myelodysplastic syndromes (MDS)	Sanz, G.F.		1997	21	1S1	p. S13	article
165	56 Prognostic impact of cytogenetic investigations in 270 patients with primary myelodysplastic syndromes	Germing, U.		1997	21	1S1	p. S15	article
166	66 Prognostic significance of serum protein electrophoresis pattern changes in patients with myelodysplastic syndromes	Symeonidis, A.		1997	21	1S1	p. S18	article
167	29 Proliferative chronic myelomonocytic leukemia (P-CMML) emerging after splenectomy in two patients with dysplastic CMML (D-CMML)	Vallespí, Teresa		1997	21	1S1	p. S8	article
168	164 Promising cyclosporin a therapy for myelodysplastic syndrome	Jonásˇová, A.		1997	21	1S1	p. S42	article
169	179 Promotion of multilineage hematopoiesis in patients with myelodysplastic syndrome: A phase I/II clinical trial with amifostine	List, A.		1997	21	1S1	p. S47	article
170	142 5q- Syndrome: Breakpoint investigation	Abdelhay, Eliana		1997	21	1S1	p. S37	article
171	154 Quality of life in persons with myelodysplastic syndromes: The neglected variable	Thomas, Mary Laudon		1997	21	1S1	p. S40	article
172	111 Recent and new characteristic chromosome abnormalities in myelodysplastic syndromes (MDS)	Mecucci, Cristina		1997	21	1S1	p. S29	article
173	46 Recent developments in the prognostic classification for MDS: Results of The International Risk Analysis Workshop	Greenberg, P.		1997	21	1S1	p. S13	article
174	72 Recruitment and identification of “normal” hematopoietic cells in MDS	Frassoni, F		1997	21	1S1	p. S19	article
175	25 Refractory anemia, pure sideroblastic anemia and refractory cytopenia with multilineage dysplasia	Rus, G. Pérez		1997	21	1S1	p. S7	article
176	42 Refractory thrombocytopenia with bone marrow dysplasia: MDS or another entity?	Ündar, B.		1997	21	1S1	p. S11	article
177	183 Results of treatment in patients with acute myeloid leukemia preceeded by primary myelodysplastic syndrome	Urbańska-Ryś, H.		1997	21	1S1	p. S48	article
178	32 Review of 100 cases considered like MDS by clinicians	Tassin, F.		1997	21	1S1	p. S9	article
179	159 r-hu-Epo and G-CSF treatment in simple and sideroblastic refractory anemias: A multicenter study	Remacha, A		1997	21	1S1	p. S41	article
180	95 Serum levels of thrombopoietin (TPO) In myelodysplasias	Fontenay-Roupie, M.		1997	21	1S1	p. S25	article
181	128 Single del(11q) in a patient with RAEB which progressed to erythroleukemia	Martinez-Climent, J.A.		1997	21	1S1	p. S33	article
182	69 Spontaneous improvement of hematological parameters in 8 patients with myelodysplastic syndromes (MDS)	Breccia, M.		1997	21	1S1	p. S18	article
183	92 Stem cell defect and the genesis of cytopenias in myelodysplastic syndromes (MDS) and their correction by amifostine	Raza, A.		1997	21	1S1	p. S24	article
184	155 Successful anti-cytokine based approach to treat myelodysplastic syndromes (MDS)	Raza, A.		1997	21	1S1	p. S40	article
185	53 Survival analysis of 60 patients with primary myelodysplastic syndromes (MDS) according to prognostic groups defined by Mufti (1992)	Souza, J.M.		1997	21	1S1	p. S14	article
186	65 Survival and outcome in 30 patienta with chronic myelomonocytic leukemia (CMML)	Shtarlid, M.		1997	21	1S1	p. S17	article
187	41 Sweet's Syndrome in neutropenic patient with myelodysplasia	Niero-Melo, L		1997	21	1S1	p. S11	article
188	167 Tamoxifen as treatment for myelodysplastic syndromes? — A case report	Uhr, M.		1997	21	1S1	p. S43	article
189	190 T-cell depleted (SBA-E-) bone marrow transplantation for myelodysplastic syndromes	Castro-Malaspina, H.		1997	21	1S1	p. S51	article
190	75 Telomere dynamics in myelodysplastic syndromes	Toyama, K.		1997	21	1S1	p. S20	article
191	76 The absolute number of CD34+ cells and CD34+ cells in S-phase increase during the evolution of myelodysplastic syndromes (MDS)	Span, L.		1997	21	1S1	p. S20	article
192	93 The combination of all-trans retinoic acid (atra) and bryostatin 1 (BRYO) induces monocytic differentation (MD) In human myeloid leukemia	Stone, R.		1997	21	1S1	p. S24	article
193	180 The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes	Vasilica, M.		1997	21	1S1	p. S48	article
194	3 The F.A.B. classification of the myelodysplastic syndromes (MDS)	Bennett, J.M.		1997	21	1S1	p. S1	article
195	8 The history of MDS: The role of the F.A.B. classification and the development of risk assessment	Bennett, John M.		1997	21	1S1	p. S3	article
196	49 The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS	De Witte, T.		1997	21	1S1	p. S13	article
197	6 The 5q- syndrome	Van den Berghe, H.		1997	21	1S1	p. S2	article
198	191 The seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS)	Anderson, J.E.		1997	21	1S1	p. S51	article
199	89 The value of cell cultures for diagnosis of mixed myelodysplastic syndromes/ myelopro-liferative disorders	del Can˜izo, M.C.		1997	21	1S1	p. S23	article
200	197 t(3;5) High-grade myelodysplasia and acute myeloid leukemia of young adults responds favorably to allogeneic bone marrow transplantation	Arber, D.A.		1997	21	1S1	p. S52	article
201	67 Thrombocytosis and sideroblastic anaemia	Ancin, I.		1997	21	1S1	p. S18	article
202	150 Treatment of low-risk MDS: Combination of hematopoietic growth factors and biological response modifiers	Hoelzer, D.		1997	21	1S1	p. S39	article
203	166 Treatment of multiple transfused patients with myelodysplastic syndromes by iron chelation with desferrioxamine	Jensen, P.D.		1997	21	1S1	p. S43	article
204	149 Treatment strategies in MDS: Who and how should be treated?	Mufti, Ghulam J.		1997	21	1S1	p. S39	article
205	204 Trilineage myelodysplasia in patients with acute myeloid leukaemia correlates with shorter disease free and overal survival	Staneva, M.		1997	21	1S1	p. S55	article

205 results found

Koninklijke Bibliotheek - National Library of the Netherlands